CACNA1G

Summary

CACNA1G (calcium voltage-gated channel subunit alpha1 G, HGNC:1394) is a protein-coding gene on chromosome 17q21.33, encoding Voltage-dependent T-type calcium channel subunit alpha-1G (O43497). Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division an….

Voltage-sensitive calcium channels mediate the entry of calcium ions into excitable cells, and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division, and cell death. This gene encodes a T-type, low-voltage activated calcium channel. The T-type channels generate currents that are both transient, owing to fast inactivation, and tiny, owing to small conductance. T-type channels are thought to be involved in pacemaker activity, low-threshold calcium spikes, neuronal oscillations and resonance, and rebound burst firing. Many alternatively spliced transcript variants encoding different isoforms have been described for this gene.

Source: NCBI Gene 8913 — RefSeq curated summary.

At a glance

• Gene–disease (curated): spinocerebellar ataxia type 42 (Definitive, ClinGen) — +3 more curated relationships
• GWAS associations: 10
• Clinical variants (ClinVar): 1,489 total — 3 pathogenic, 26 likely-pathogenic
• Phenotypes (HPO): 74
• Druggable target: yes — 8 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_018896

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1394
Approved symbol	CACNA1G
Name	calcium voltage-gated channel subunit alpha1 G
Location	17q21.33
Locus type	gene with protein product
Status	Approved
Aliases	Cav3.1, NBR13
Ensembl gene	ENSG00000006283
Ensembl biotype	protein_coding
OMIM	604065
Entrez	8913

Gene structure

Transcript identifiers

Ensembl transcripts: 34 — 28 protein_coding, 6 nonsense_mediated_decay

ENST00000352832, ENST00000354983, ENST00000358244, ENST00000359106, ENST00000360761, ENST00000416767, ENST00000429973, ENST00000442258, ENST00000502264, ENST00000503436, ENST00000503485, ENST00000503607, ENST00000504076, ENST00000505165, ENST00000506406, ENST00000506520, ENST00000507336, ENST00000507510, ENST00000507609, ENST00000507896, ENST00000510115, ENST00000510366, ENST00000511765, ENST00000511768, ENST00000512389, ENST00000513689, ENST00000513964, ENST00000514079, ENST00000514181, ENST00000514717, ENST00000515165, ENST00000515411, ENST00000515765, ENST00000570567

RefSeq mRNA: 28 — MANE Select: NM_018896 NM_001256324, NM_001256325, NM_001256326, NM_001256327, NM_001256328, NM_001256329, NM_001256330, NM_001256331, NM_001256332, NM_001256333, NM_001256334, NM_001256359, NM_001256360, NM_001256361, NM_018896, NM_198376, NM_198377, NM_198378, NM_198379, NM_198380, NM_198382, NM_198383, NM_198384, NM_198385, NM_198386, NM_198387, NM_198388, NM_198396

CCDS: CCDS45730, CCDS45731, CCDS45732, CCDS45733, CCDS45734, CCDS45735, CCDS45736, CCDS45737, CCDS54142, CCDS54143, CCDS54144, CCDS54145, CCDS54146, CCDS58565, CCDS58566, CCDS58567, CCDS58568, CCDS58569, CCDS58570, CCDS58571, CCDS58572, CCDS58573, CCDS58574, CCDS58575, CCDS58576

Canonical transcript exons

ENST00000359106 — 38 exons

Exon	Start	End
ENSE00000418781	50605898	50606023
ENSE00000737388	50615361	50615512
ENSE00000737390	50616275	50616384
ENSE00000947003	50609882	50609935
ENSE00000947004	50619683	50619826
ENSE00000947005	50621660	50621794
ENSE00001599683	50606900	50606989
ENSE00001614472	50617859	50617929
ENSE00001617425	50618048	50618126
ENSE00001715296	50607827	50608019
ENSE00001718074	50617438	50617571
ENSE00002049844	50626017	50627474
ENSE00002433061	50578188	50578564
ENSE00002454632	50569706	50569803
ENSE00002458652	50573021	50573113
ENSE00002474516	50569165	50569298
ENSE00002478332	50591435	50591620
ENSE00002481036	50591937	50592092
ENSE00002481598	50602820	50602888
ENSE00002486793	50596730	50596923
ENSE00002490299	50575543	50576326
ENSE00002490980	50591739	50591853
ENSE00002491921	50590471	50590622
ENSE00002493674	50596562	50596646
ENSE00002501231	50572554	50572854
ENSE00002511875	50571878	50572037
ENSE00002514749	50568870	50568981
ENSE00002517095	50603015	50603199
ENSE00002529934	50599428	50599859
ENSE00002531395	50600726	50600826
ENSE00002532045	50604155	50604281
ENSE00002533559	50601051	50601174
ENSE00002533683	50594993	50595061
ENSE00003634408	50623907	50624075
ENSE00003650189	50624360	50624529
ENSE00003657929	50618222	50618343
ENSE00003676398	50618655	50619008
ENSE00003848780	50560715	50561701

Expression profiles

Bgee: expression breadth ubiquitous, 194 present calls, max score 91.36.

FANTOM5 (CAGE): breadth broad, TPM avg 2.6482 / max 200.9295, expressed in 521 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161687	1.9730	461
161688	0.6046	240
161689	0.0706	30

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lateral nuclear group of thalamus	UBERON:0002736	91.36	gold quality
right hemisphere of cerebellum	UBERON:0014890	84.13	gold quality
right frontal lobe	UBERON:0002810	80.92	gold quality
primary visual cortex	UBERON:0002436	79.82	gold quality
cerebellar vermis	UBERON:0004720	79.59	silver quality
endothelial cell	CL:0000115	79.49	silver quality
prefrontal cortex	UBERON:0000451	79.39	gold quality
cerebellum	UBERON:0002037	79.26	gold quality
orbitofrontal cortex	UBERON:0004167	78.94	gold quality
cerebellar cortex	UBERON:0002129	78.62	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	78.56	gold quality
cerebellar hemisphere	UBERON:0002245	78.52	gold quality
frontal cortex	UBERON:0001870	78.42	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.40	silver quality
postcentral gyrus	UBERON:0002581	78.35	gold quality
superior frontal gyrus	UBERON:0002661	77.72	gold quality
occipital lobe	UBERON:0002021	77.63	gold quality
neocortex	UBERON:0001950	77.50	gold quality
parietal lobe	UBERON:0001872	77.47	gold quality
parotid gland	UBERON:0001831	77.26	gold quality
endocervix	UBERON:0000458	76.93	gold quality
dorsal plus ventral thalamus	UBERON:0001897	76.91	gold quality
Brodmann (1909) area 9	UBERON:0013540	76.79	gold quality
ectocervix	UBERON:0012249	75.87	gold quality
hypothalamus	UBERON:0001898	75.69	gold quality
cerebral cortex	UBERON:0000956	75.34	gold quality
cingulate cortex	UBERON:0003027	74.83	gold quality
anterior cingulate cortex	UBERON:0009835	74.70	gold quality
Brodmann (1909) area 46	UBERON:0006483	74.68	gold quality
cartilage tissue	UBERON:0002418	73.77	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.97

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTNNB1, LEF1, SP1, WNT3A

miRNA regulators (miRDB)

59 targeting CACNA1G, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-8076	99.78	68.52	1170
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-6733-5P	99.74	67.94	2759

Literature-anchored findings (GeneRIF, showing 40)

• Specific contribution of human T-type calcium channel isotypes (alpha(1G), alpha(1H) and alpha(1I)) to neuronal excitability. (PMID:11927664)
• Since allele and genotype distributions of CACNA1G polymorphisms in cases studied are not remarkably different from control groups, CACNA1G is not an important susceptibility gene for childhood absence epilepsy in the Han Chinese population. (PMID:12676336)
• The down-regulation of alpha 1G T-type calcium channel mRNA in differentiated Y79 cells is mediated primarily by decreased activity of promoter A, which could occur in conjunction with repression of the activity of promoter B. (PMID:12752779)
• Data describe the construction of a new cell line stably expressing alpha(1G) and Kir2.1 subunits in HEK293 cells. (PMID:15465033)
• T-type voltage-operated Ca2+ channels are required for cell cycle progression and proliferation of human pulmonary artery smooth muscle cell. (PMID:15774856)
• CACNA1G is a human gene for T-type Ca(v)3.1 calcium channels that is subject to extensive alternative RNA splicing (PMID:16671074)
• collective findings flag CACNA1G as a potential susceptibility locus for idiopathic generalized epilepsy subsyndromes (PMID:17397049)
• Primary T-type subunit expressed in some myometrial smooth muscle cells is Cav3.1. (PMID:17446221)
• A panel of markers including at least RUNX3, CACNA1G, IGF2, and MLH1 can serve as a sensitive and specific marker panel for CIMP(Cpg island methylator phenotype)-high. (PMID:17591929)
• The sodium channel toxins tetrodotoxin and saxitoxin interact with the alpha-subunit of T-type Ca 2+ channels. (PMID:18591418)
• This study reports the concentration dependence of currents through Ca(V)3.1 T-type calcium channels stably expressed in HEK 293 cells. (PMID:18663131)
• A study evaluating whether the effect of Ni(2+) on Ca(V)3.1 is affected by permeant ions is reported. (PMID:18663132)
• These results suggest that RanBPM could be a key regulator of Ca(v)3.1 channel-mediated signaling pathways. (PMID:18801335)
• Elevated brain levels of Cacna1g channel identify a key causal component of pure absence epilepsy and a major genetic component of the epileptogenic pathway. (PMID:19211869)
• establishing CACNA1G as a novel candidate gene for autism, these alleles do not contribute a sufficient genetic effect to explain the observed linkage, indicating that there is substantial genetic heterogeneity despite the clear linkage signal (PMID:19455149)
• Results reveal an intracellular WPb-independent P-selectin pool in pulmonary capillary endothelium, where the regulated P-selectin surface expression is triggered by Ca(2+) transients evoked through activation of the alpha(1G) T-type channel. (PMID:20435690)
• The function of T-type Ca(2+) channels is important for the proliferation of human ovarian cancer cells. (PMID:21438841)
• Data showed expression of L-type (Ca(v) 1.2), P/Q-type (Ca(v) 2.1), and T-type subtype (Ca(v) 3.1 and Ca(v) 3.2) voltage-gated calcium channels (Ca(v)s) in renal artery and dissected intrarenal blood vessels from nephrectomies. (PMID:21788606)
• Cav3.1 channels may contribute to the repression of tumor proliferation and the promotion of apoptosis mediated via Cav3.1-specific calcium signals (PMID:22469755)
• Augmentation of CaV3.1 currents by Ras-ERK activation is associated with enhanced trafficking of channels to the plasma membrane. (PMID:22572848)
• The abnormal mRNA expressions of T-type channel alpha1H and alpha1G may be one of the causes of declined semen quality and infertility in varicocele patients. (PMID:22574369)
• Cd(2) carried sizable inward currents through Ca(v)3.1 channels (210 +/- 20 pA at -60 mV with 2 mM Cd(2)). (PMID:22973059)
• Ca(V)3.1 channels represent a likely pathway for Fe(2) entry into cells. (PMID:22973060)
• Ethanol affects CaV3.2 but not CaV3.1 nor CaV3.3 channel isoforms. (PMID:23488970)
• CaV3.1 downregulation is a major initiating factor for the increased production of the toxic Ab peptide, then the CaV3.1 T-type calcium channel represents a novel target for preventative therapeutics in Alzheimer’s disease. (PMID:24268883)
• CaV3.1 channel is required for the generation of a given set of thalamocortical rhythms during unconsciousness. Further, that thalamocortical resonant neuronal activity supported by this channel is important for the control of vigilance states (PMID:26056284)
• A Recurrent Mutation in CACNA1G Alters Cav3.1 T-Type Calcium-Channel Conduction and Causes Autosomal-Dominant Cerebellar Ataxia. (PMID:26456284)
• CaV3.1, CaV3.2 and CaV3.3 channels, are best recognized for their negative voltage of activation and inactivation thresholds that allow them to operate near the resting membrane potential of neurons. (PMID:26488564)
• In 2 families with autosomal dominant SCA, a CACNA1G mutation p.Arg1715His was found at S4 of repeat IV, the voltage sensor of the CaV3.1 which shifted it toward a positive potential. (PMID:26715324)
• Electrophysiological studies showed a significant increase in Cd(2+) and manganese (Mn(2+)) currents through the CaV3.1 mutants as well as a reduction in the inhibitory effect of Cd(2+) on the Ca(2+) current. (PMID:27134080)
• CACNA1G variant is associated with differential antiepileptic drug response in childhood absence epilepsy. (PMID:28165634)
• The results of this study provide support for Cacna1g as a genetic modifier in a mouse model of Dravet syndrome and suggest that Cav3.1 may be a potential molecular target for therapeutic intervention in patients (PMID:28556246)
• Here we show that T-type channels Cav3.1 and Cav3.2 are present in the lung and PASMCs from iPAH patients and control subjects. The blockade of T-type channels by the specific blocker, TTA-A2, prevents cell cycle progression and PASMCs growth (PMID:28655554)
• T-type channel calcium influx invokes a novel dynamic interaction between CaM and Cav3.1 channels to trigger a signaling cascade that leads to alphaCaMKII activation. (PMID:28800734)
• Cacna1g exclusively expressed in serosal PDGFRalpha+ cells is a new pathological marker for gastrointestinal diseases. (PMID:28806761)
• In gastric cancer, expression of all the CACNA (1G, 1H, 1I) genes was associated with overall survival (OS) among stage I-IV patients. By combining the three potential biomarkers, a TTCC signature was developed, which retained a significant association with OS both in stage IV and stage I-III patients. Alterations in CACNA gene expression are linked to tumour prognosis. (PMID:28846697)
• human Cav3.1, Cav3.2, and Cav3.3 T-type channels specifically associate with CaM at helix 2 of the gating brake in the I-II linker of the channels. (PMID:28972185)
• Cav3.1 and LC3-II proteins are highly expressed in BRAFV600E compared with NRAS mutant melanomas, both in cell lines and biopsies. (PMID:29385656)
• CACNA1G-AS1 was identified as an oncogene in non-small cell lung cancer, promoting cell invasion and migration via increasing HNRNPA2B1 expression. (PMID:29509247)
• These findings reveal spectrin (alpha/beta) / ankyrin B cytoskeletal and signaling proteins as key regulators of T-type calcium channels expressed in the nervous system. (PMID:29720258)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cacna1g	ENSDARG00000089913
mus_musculus	Cacna1g	ENSMUSG00000020866
rattus_norvegicus	Cacna1g	ENSRNOG00000060528

Paralogs (26): SCN4A (ENSG00000007314), CACNA1S (ENSG00000081248), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), NALCN (ENSG00000102452), SCN2A (ENSG00000136531), SCN7A (ENSG00000136546), CACNA1A (ENSG00000141837), SCN1A (ENSG00000144285), CACNA1B (ENSG00000148408), CACNA1C (ENSG00000151067), CATSPER3 (ENSG00000152705), SCN3A (ENSG00000153253), CACNA1D (ENSG00000157388), TPCN2 (ENSG00000162341), CATSPER2 (ENSG00000166762), SCN11A (ENSG00000168356), SCN9A (ENSG00000169432), CATSPER1 (ENSG00000175294), SCN5A (ENSG00000183873), SCN10A (ENSG00000185313), TPCN1 (ENSG00000186815), CATSPER4 (ENSG00000188782), CACNA1H (ENSG00000196557), SCN8A (ENSG00000196876), CACNA1E (ENSG00000198216)

Protein

Protein identifiers

Voltage-dependent T-type calcium channel subunit alpha-1G — O43497 (reviewed: O43497)

Alternative names: Cav3.1c, NBR13, Voltage-gated calcium channel subunit alpha Cav3.1

All UniProt accessions (4): O43497, A0A0B4J1X2, H0YAN0, I3L2W8

UniProt curated annotations — full annotation on UniProt →

Function. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the ’low-voltage activated (LVA)’ group and are strongly blocked by mibefradil. A particularity of this type of channel is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents.

Subcellular location. Cell membrane. Cytoplasm.

Tissue specificity. Highly expressed in brain, in particular in the amygdala, subthalamic nuclei, cerebellum and thalamus. Moderate expression in heart; low expression in placenta, kidney and lung. Also expressed in colon and bone marrow and in tumoral cells to a lesser extent. Highly expressed in fetal brain, but also in peripheral fetal tissues as heart, kidney and lung, suggesting a developmentally regulated expression.

Post-translational modifications. In response to raising of intracellular calcium, the T-type channels are activated by CaM-kinase II.

Disease relevance. Spinocerebellar ataxia 42 (SCA42) [MIM:616795] A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA42 is a slowly progressive, autosomal dominant form with variable severity. The disease is caused by variants affecting the gene represented in this entry. Spinocerebellar ataxia 42, early-onset, severe, with neurodevelopmental deficits (SCA42ND) [MIM:618087] A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA42ND is an early-onset, severe form associated with motor and cognitive impairment, cerebellar atrophy as well as variable features such as facial dysmorphisms, digital anomalies, microcephaly and epilepsy. SCA42ND inheritance is autosomal dominant. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. Each of the four internal repeats contains five hydrophobic transmembrane segments (S1, S2, S3, S5, S6) and one positively charged transmembrane segment (S4). S4 segments probably represent the voltage-sensor and are characterized by a series of positively charged amino acids at every third position. The linker region between repeat III and IV probably plays a role in the inactivation of the channel. The C-terminal part may be implicated in the anchoring of the protein to the membrane by interfering with or restricting its lateral diffusion.

Similarity. Belongs to the calcium channel alpha-1 subunit (TC 1.A.1.11) family. CACNA1G subfamily.

Isoforms (35)

UniProt ID	Names	Canonical?
O43497-1	5	yes
O43497-2	1, Variant 89
O43497-3	2, Variant 25, alpha-1G-b
O43497-4	3
O43497-5	4, Variant 88
O43497-6	6, Variant 217
O43497-7	7, Variant 221
O43497-8	8, Variant 93
O43497-9	9, Variant 57
O43497-10	10
O43497-11	11, Variant 185
O43497-12	12, Variant 189
O43497-13	13, Variant 153
O43497-15	14, Variant 137
O43497-16	15, Variant 157
O43497-17	16, Variant 169
O43497-18	17, Variant 184
O43497-19	18, Variant 216
O43497-20	19, Variant 223
O43497-21	20, Variant 249
O43497-22	21, Variant 313
O43497-23	22, Variant 409
O43497-24	23, Variant 441
O43497-25	24, Variant 477
O43497-26	25, Variant 473
O43497-27	26, Variant 17
O43497-28	27, Variant 33
O43497-29	28, Variant 49
O43497-30	29, Variant 145
O43497-31	30, Variant 177
O43497-32	31, Variant 209
O43497-33	32
O43497-34	33, Variant 441-d81
O43497-35	34, Variant 473-d75
O43497-36	35, Variant 473-d81

RefSeq proteins (28): NP_001243253, NP_001243254, NP_001243255, NP_001243256, NP_001243257, NP_001243258, NP_001243259, NP_001243260, NP_001243261, NP_001243262, NP_001243263, NP_001243288, NP_001243289, NP_001243290, NP_061496, NP_938190, NP_938191, NP_938192, NP_938193, NP_938194, NP_938196, NP_938197, NP_938198, NP_938199, NP_938200, NP_938201, NP_938202, NP_938406 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002077	VDCCAlpha1	Family
IPR005445	VDCC_T_a1	Family
IPR005821	Ion_trans_dom	Domain
IPR027359	Volt_channel_dom_sf	Homologous_superfamily
IPR050599	VDCC_alpha-1_subunit	Family

Pfam: PF00520

Catalyzed reactions (Rhea), 1 shown:

• Ca(2+)(in) = Ca(2+)(out) (RHEA:29671)

UniProt features (182 total): helix 55, topological domain 25, transmembrane region 24, splice variant 16, strand 12, region of interest 10, turn 8, glycosylation site 8, compositionally biased region 6, modified residue 5, repeat 4, site 4, sequence variant 3, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
6KZP	ELECTRON MICROSCOPY	3.1
6KZO	ELECTRON MICROSCOPY	3.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43497-F1	59.36	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (4): 354 (calcium ion selectivity and permeability); 924 (calcium ion selectivity and permeability); 1465 (calcium ion selectivity and permeability); 1770 (calcium ion selectivity and permeability)

Post-translational modifications (5): 467, 715, 1139, 1145, 1146

Glycosylation sites (8): 173, 246, 306, 310, 322, 1448, 1451, 1698

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-419037	NCAM1 interactions
R-HSA-445355	Smooth Muscle Contraction
R-HSA-1266738	Developmental Biology
R-HSA-375165	NCAM signaling for neurite out-growth
R-HSA-397014	Muscle contraction
R-HSA-422475	Axon guidance
R-HSA-9675108	Nervous system development

MSigDB gene sets: 369 (showing top): TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_DN, GOBP_MEMBRANE_DEPOLARIZATION, AAGCAAT_MIR137, GOBP_MUSCLE_TISSUE_DEVELOPMENT, BENPORATH_ES_WITH_H3K27ME3, GOBP_CIRCULATORY_SYSTEM_PROCESS, LFA1_Q6, KEGG_MAPK_SIGNALING_PATHWAY, SP3_Q3, GOBP_MEMBRANE_DEPOLARIZATION_DURING_ACTION_POTENTIAL, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH, SATO_SILENCED_BY_DEACETYLATION_IN_PANCREATIC_CANCER, SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER, AP4_Q6

GO Biological Process (24): sinoatrial node development (GO:0003163), chemical synaptic transmission (GO:0007268), response to nickel cation (GO:0010045), regulation of membrane potential (GO:0042391), regulation of atrial cardiac muscle cell membrane depolarization (GO:0060371), calcium ion import (GO:0070509), calcium ion transmembrane transport (GO:0070588), cardiac muscle cell action potential involved in contraction (GO:0086002), SA node cell action potential (GO:0086015), AV node cell action potential (GO:0086016), SA node cell to atrial cardiac muscle cell signaling (GO:0086018), AV node cell to bundle of His cell signaling (GO:0086027), membrane depolarization during AV node cell action potential (GO:0086045), membrane depolarization during SA node cell action potential (GO:0086046), regulation of heart rate by cardiac conduction (GO:0086091), calcium ion import across plasma membrane (GO:0098703), action potential (GO:0001508), regulation of heart rate (GO:0002027), monoatomic ion transport (GO:0006811), calcium ion transport (GO:0006816), monoatomic ion transmembrane transport (GO:0034220), transmembrane transport (GO:0055085), regulation of biological quality (GO:0065008), monoatomic cation transmembrane transport (GO:0098655)

GO Molecular Function (9): voltage-gated calcium channel activity (GO:0005245), high voltage-gated calcium channel activity (GO:0008331), low voltage-gated calcium channel activity (GO:0008332), voltage-gated calcium channel activity involved in AV node cell action potential (GO:0086056), voltage-gated calcium channel activity involved SA node cell action potential (GO:0086059), scaffold protein binding (GO:0097110), monoatomic ion channel activity (GO:0005216), monoatomic cation channel activity (GO:0005261), calcium channel activity (GO:0005262)

GO Cellular Component (6): cytoplasm (GO:0005737), plasma membrane (GO:0005886), voltage-gated calcium channel complex (GO:0005891), synapse (GO:0045202), membrane (GO:0016020), monoatomic ion channel complex (GO:0034702)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
NCAM signaling for neurite out-growth	1
Muscle contraction	1
Axon guidance	1
Nervous system development	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cardiac muscle cell action potential	3
regulation of biological quality	2
calcium ion transport	2
membrane depolarization during cardiac muscle cell action potential	2
AV node cell action potential	2
SA node cell action potential	2
voltage-gated calcium channel activity	2
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	2
cellular anatomical structure	2
cardiac conduction system development	1
atrial cardiac muscle tissue development	1
anterograde trans-synaptic signaling	1
response to metal ion	1
monoatomic ion transmembrane transport	1
regulation of membrane depolarization	1
monoatomic cation transmembrane transport	1
cardiac muscle cell contraction	1
SA node cell to atrial cardiac muscle cell signaling	1
AV node cell to bundle of His cell signaling	1
SA node cell to atrial cardiac muscle cell communication	1
AV node cell to bundle of His cell communication	1
regulation of heart rate	1
cardiac conduction	1
calcium ion import	1
calcium ion transmembrane import into cytosol	1
inorganic cation import across plasma membrane	1
calcium ion import into cytosol	1
regulation of membrane potential	1
regulation of heart contraction	1
transport	1
metal ion transport	1
calcium channel activity	1
voltage-gated monoatomic cation channel activity	1
membrane depolarization during AV node cell action potential	1
membrane depolarization during SA node cell action potential	1
protein binding	1
monoatomic ion transmembrane transporter activity	1
channel activity	1
monoatomic ion channel activity	1
monoatomic cation transmembrane transporter activity	1

Protein interactions and networks

STRING

1664 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CACNA1G	GNB2	P11016	825
CACNA1G	NEUROG1	Q92886	808
CACNA1G	CALM1	P02593	802
CACNA1G	CALML3	P27482	797
CACNA1G	CALML5	Q9NZT1	796
CACNA1G	CAV3	P56539	793
CACNA1G	CALML6	Q8TD86	787
CACNA1G	CALML4	Q96GE6	787
CACNA1G	CRABP1	P29762	765
CACNA1G	GNG2	P59768	754
CACNA1G	CACNA2D2	Q9NY47	734
CACNA1G	RUNX3	Q13761	728
CACNA1G	SOCS1	O15524	697
CACNA1G	GABBR1	Q9UBS5	695
CACNA1G	MLH1	P40692	674

IntAct

4 interactions, top by confidence:

A	B	Type	Score
MYC		psi-mi:“MI:0914”(association)	0.350
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350
UBQLN4	CACNA1G	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (9): RANBP9 (Two-hybrid), CACNA1G (Affinity Capture-MS), CACNA1G (Affinity Capture-MS), CACNA1G (Affinity Capture-MS), ECI1 (Cross-Linking-MS (XL-MS)), CACNA1G (Affinity Capture-MS), PAXBP1 (Cross-Linking-MS (XL-MS)), CACNA1G (Co-fractionation), CACNA1G (Two-hybrid)

ESM2 similar proteins: A2ARP9, B1AYL1, D0E0C2, F1LQQ7, O08562, O14234, O35505, O43497, O46669, O54898, O55017, O73700, O88457, P02719, P0DMA5, P15381, P15390, P22002, P27732, P50077, P56698, P56699, P59111, Q01118, Q02294, Q02343, Q07652, Q13936, Q15858, Q15878, Q28371, Q28644, Q61290, Q62205, Q62968, Q6AXP6, Q6QIY3, Q7RTX7, Q80W99, Q86XQ3

Diamond homologs: A1L3P4, A3RL54, D3ZJ86, G3XD29, O43497, P74393, Q3YL57, Q8BLV3, Q92581, Q93HU4, Q9LCB5, Q9LKW9, A2APX8, A2ASI5, B1AWN6, B1AYL1, C9D7C2, D0E0C2, O00555, O08562, O35505, O42398, O46669, O55017, O57483, O60840, O73700, O73705, O73706, O73707, O88420, O88427, O88457, O95180, P02719, P04774, P04775, P07293, P08104, P0DMA5

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
CACNA1G	“up-regulates quantity”	calcium(2+)	relocalization
CACNA1G	up-regulates	Excitatory_synaptic_transmission
CACNA1G	up-regulates	Action_potential
SP1	“up-regulates quantity by expression”	CACNA1G	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

1489 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	26
Uncertain significance	791
Likely benign	397
Benign	108

Top pathogenic / likely-pathogenic (29)

Variant ID	HGVS	Classification
221981	NM_018896.5(CACNA1G):c.5144G>A (p.Arg1715His)	Pathogenic
280269	NM_018896.5(CACNA1G):c.2881G>A (p.Ala961Thr)	Pathogenic
559581	NM_018896.5(CACNA1G):c.4591A>G (p.Met1531Val)	Pathogenic
1027428	NM_018896.5(CACNA1G):c.2740G>A (p.Val914Ile)	Likely pathogenic
1027464	NM_018896.5(CACNA1G):c.5395T>A (p.Ser1799Thr)	Likely pathogenic
1027472	NM_018896.5(CACNA1G):c.3835G>A (p.Asp1279Asn)	Likely pathogenic
1228386	NM_018896.5(CACNA1G):c.2810C>T (p.Ser937Leu)	Likely pathogenic
1332877	NM_018896.5(CACNA1G):c.4594T>C (p.Phe1532Leu)	Likely pathogenic
1700076	NM_018896.5(CACNA1G):c.5152C>G (p.Arg1718Gly)	Likely pathogenic
1718753	NM_018896.5(CACNA1G):c.337C>A (p.Arg113Ser)	Likely pathogenic
1722930	NM_018896.5(CACNA1G):c.590T>G (p.Met197Arg)	Likely pathogenic
1804078	NM_018896.5(CACNA1G):c.4592T>C (p.Met1531Thr)	Likely pathogenic
183285	NM_018896.5(CACNA1G):c.664TTC[1] (p.Phe223del)	Likely pathogenic
2500266	NM_018896.5(CACNA1G):c.2549C>T (p.Ala850Val)	Likely pathogenic
2575085	NM_018896.5(CACNA1G):c.4593G>A (p.Met1531Ile)	Likely pathogenic
265067	NM_018896.5(CACNA1G):c.2599A>C (p.Thr867Pro)	Likely pathogenic
3234634	NM_018896.5(CACNA1G):c.626C>T (p.Pro209Leu)	Likely pathogenic
3256767	NM_018896.5(CACNA1G):c.4591A>T (p.Met1531Leu)	Likely pathogenic
3359074	NM_018896.5(CACNA1G):c.5543C>G (p.Ala1848Gly)	Likely pathogenic
3359834	NM_018896.5(CACNA1G):c.556C>T (p.Arg186Ter)	Likely pathogenic
3381757	NM_018896.5(CACNA1G):c.3787T>G (p.Ser1263Ala)	Likely pathogenic
3382414	NM_018896.5(CACNA1G):c.4931A>T (p.Lys1644Met)	Likely pathogenic
3382661	NM_018896.5(CACNA1G):c.4180C>T (p.Arg1394Trp)	Likely pathogenic
3390633	NM_018896.5(CACNA1G):c.277C>T (p.Leu93Phe)	Likely pathogenic
422268	NM_018896.5(CACNA1G):c.1890C>G (p.Ser630Arg)	Likely pathogenic
452482	NM_018896.5(CACNA1G):c.623T>C (p.Leu208Pro)	Likely pathogenic
808297	NM_018896.5(CACNA1G):c.4601G>A (p.Gly1534Asp)	Likely pathogenic
871462	NM_018896.5(CACNA1G):c.1103C>T (p.Ser368Phe)	Likely pathogenic
974856	NM_018896.5(CACNA1G):c.632T>C (p.Leu211Pro)	Likely pathogenic

SpliceAI

7210 predictions. Top by Δscore:

Variant	Effect	Δscore
17:50568983:T:G	donor_loss	1.0000
17:50569159:C:G	acceptor_gain	1.0000
17:50569160:A:AG	acceptor_gain	1.0000
17:50569160:ATCAG:A	acceptor_gain	1.0000
17:50569161:T:G	acceptor_gain	1.0000
17:50569161:TCA:T	acceptor_loss	1.0000
17:50569162:CAGGC:C	acceptor_loss	1.0000
17:50569163:A:AG	acceptor_gain	1.0000
17:50569163:A:C	acceptor_loss	1.0000
17:50569164:G:GG	acceptor_gain	1.0000
17:50569194:T:TA	acceptor_gain	1.0000
17:50569197:C:A	acceptor_gain	1.0000
17:50569199:T:TA	acceptor_gain	1.0000
17:50569294:GCAGG:G	donor_gain	1.0000
17:50569296:AGGG:A	donor_loss	1.0000
17:50569297:GG:G	donor_gain	1.0000
17:50569298:GG:G	donor_gain	1.0000
17:50569299:G:GG	donor_gain	1.0000
17:50569299:GTG:G	donor_loss	1.0000
17:50569804:G:GG	donor_gain	1.0000
17:50571872:CCACA:C	acceptor_loss	1.0000
17:50571873:CACAG:C	acceptor_loss	1.0000
17:50571874:ACAGG:A	acceptor_loss	1.0000
17:50571875:CAGG:C	acceptor_loss	1.0000
17:50571876:A:T	acceptor_loss	1.0000
17:50571877:G:GC	acceptor_loss	1.0000
17:50571877:GGCAT:G	acceptor_gain	1.0000
17:50572034:GCCT:G	donor_gain	1.0000
17:50572035:CCTG:C	donor_loss	1.0000
17:50572037:TGTG:T	donor_loss	1.0000

AlphaMissense

15574 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:50572012:T:A	C241S	1.000
17:50572012:T:C	C241R	1.000
17:50572013:G:A	C241Y	1.000
17:50572013:G:C	C241S	1.000
17:50572013:G:T	C241F	1.000
17:50572014:C:G	C241W	1.000
17:50572618:T:A	C271S	1.000
17:50572618:T:C	C271R	1.000
17:50572619:G:A	C271Y	1.000
17:50572619:G:C	C271S	1.000
17:50572620:C:G	C271W	1.000
17:50572651:T:A	C282S	1.000
17:50572651:T:C	C282R	1.000
17:50572652:G:C	C282S	1.000
17:50572653:C:G	C282W	1.000
17:50572753:T:A	W316R	1.000
17:50572753:T:C	W316R	1.000
17:50572755:G:C	W316C	1.000
17:50572755:G:T	W316C	1.000
17:50572774:T:A	C323S	1.000
17:50572774:T:C	C323R	1.000
17:50572775:G:A	C323Y	1.000
17:50572775:G:C	C323S	1.000
17:50572776:C:G	C323W	1.000
17:50572837:T:A	W344R	1.000
17:50572837:T:C	W344R	1.000
17:50573036:G:C	G355R	1.000
17:50573036:G:T	G355C	1.000
17:50573039:T:A	W356R	1.000
17:50573039:T:C	W356R	1.000

dbSNP variants (sampled 300 via entrez): RS1000032034 (17:50581369 G>A), RS1000075862 (17:50558945 T>G), RS1000134993 (17:50619289 G>C), RS1000199399 (17:50620837 C>T), RS1000236464 (17:50565891 T>C), RS1000243800 (17:50560003 A>T), RS1000269937 (17:50590810 CTT>C), RS1000284580 (17:50586841 G>T), RS1000296300 (17:50559815 C>T), RS1000402718 (17:50622973 G>A), RS1000417142 (17:50622634 G>A), RS1000438765 (17:50592509 G>A), RS1000448066 (17:50596436 C>T), RS1000450826 (17:50585376 G>A), RS1000463277 (17:50619086 C>A,G,T)

Disease associations

OMIM: gene MIM:604065 | disease phenotypes: MIM:108600, MIM:616795, MIM:618087, MIM:254770, MIM:606904

GenCC curated gene-disease

Disease	Classification	Inheritance
spinocerebellar ataxia type 42	Definitive	Autosomal dominant
spinocerebellar ataxia 42, early-onset, severe, with neurodevelopmental deficits	Definitive	Autosomal dominant
intellectual disability	Limited	Autosomal recessive
neurodevelopmental disorder	Limited	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
spinocerebellar ataxia type 42	Definitive	AD

Mondo (10): spastic ataxia (MONDO:0017845), spinocerebellar ataxia type 42 (MONDO:0014776), spinocerebellar ataxia 42, early-onset, severe, with neurodevelopmental deficits (MONDO:0060758), intellectual disability (MONDO:0001071), juvenile myoclonic epilepsy (MONDO:0009696), vascular disorder (MONDO:0005385), cerebellar ataxia (MONDO:0000437), hereditary cerebellar ataxia (MONDO:0100310), epilepsy (MONDO:0005027), neurodevelopmental disorder (MONDO:0700092)

Orphanet (5): Spastic ataxia (Orphanet:316226), Spinocerebellar ataxia type 42 (Orphanet:458803), Juvenile myoclonic epilepsy (Orphanet:307), Rare ataxia (Orphanet:102002), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

74 total (30 of 74 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000012	Urinary urgency
HP:0000020	Urinary incontinence
HP:0000252	Microcephaly
HP:0000303	Mandibular prognathia
HP:0000316	Hypertelorism
HP:0000486	Strabismus
HP:0000490	Deeply set eye
HP:0000540	Hypermetropia
HP:0000571	Hypometric saccades
HP:0000582	Upslanted palpebral fissure
HP:0000639	Nystagmus
HP:0000651	Diplopia
HP:0000657	Oculomotor apraxia
HP:0000666	Horizontal nystagmus
HP:0000716	Depression
HP:0000750	Delayed speech and language development
HP:0000802	Impotence
HP:0001007	Hirsutism
HP:0001152	Saccadic smooth pursuit interruptions
HP:0001159	Syndactyly
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001251	Ataxia
HP:0001257	Spasticity
HP:0001260	Dysarthria
HP:0001263	Global developmental delay
HP:0001272	Cerebellar atrophy
HP:0001310	Dysmetria
HP:0001317	Abnormal cerebellum morphology

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST001915_39	Alzheimer’s disease (cognitive decline)	1.000000e-09
GCST007203_9	Total cholesterol levels	3.000000e-06
GCST007324_142	Adventurousness	3.000000e-10
GCST007324_49	Adventurousness	4.000000e-08
GCST010320_102	PR interval	8.000000e-25
GCST010321_56	PR interval	3.000000e-25
GCST010796_1593	Electrocardiogram morphology (amplitude at temporal datapoints)	8.000000e-09
GCST010796_1594	Electrocardiogram morphology (amplitude at temporal datapoints)	9.000000e-09
GCST010796_1595	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-08
GCST010796_1596	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-08

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004574	total cholesterol measurement
EFO:0008579	risk-taking behaviour
EFO:0004462	PR interval
EFO:0004327	electrocardiography

MeSH disease descriptors (7)

Descriptor	Name	Tree numbers
D002524	Cerebellar Ataxia	C10.228.140.252.190; C10.597.350.090.500; C23.888.592.350.090.200
D004827	Epilepsy	C10.228.140.490
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D020190	Myoclonic Epilepsy, Juvenile	C10.228.140.490.375.130.670; C10.228.140.490.493.063.670
D065886	Neurodevelopmental Disorders	F03.625
D014652	Vascular Diseases	C14.907
C564815	Spastic Ataxia (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL2362995 (PROTEIN FAMILY), CHEMBL2363032 (PROTEIN COMPLEX GROUP), CHEMBL4641 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

8 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 104,690 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1428	NIMODIPINE	4	32,587
CHEMBL95	TACRINE	4	35,360
CHEMBL1423	PIMOZIDE	4	17,310
CHEMBL45816	MIBEFRADIL	4	7,838
CHEMBL1684950	SUVECALTAMIDE	2	70
CHEMBL30008	FLUNARIZINE	2	11,439
CHEMBL4217292	APINOCALTAMIDE	2	37
CHEMBL3934636	ULIXACALTAMIDE	1	49

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: vgic — Voltage-gated calcium channels (Ca_V)

Most potent curated ligand interactions (15 total), top 15:

Ligand	Action	Affinity	Parameter
suvecaltamide	Inhibition	8.92	pIC50
ACT-709478	Inhibition	8.19	pIC50
kurtoxin	Antagonist	7.8	pIC50
pimozide	Antagonist	7.5	pIC50
ulixacaltamide	Pore blocker	7.3	pIC50
(-)-(R)-efonidipine	Antagonist	7.0	pIC50
TTA-P2	Pore blocker	7.0	pIC50
TTA-A2	Pore blocker	7.0	pIC50
mibefradil	Antagonist	6.6	pIC50
ML218	Pore blocker	6.5	pIC50
flunarizine	Antagonist	6.27	pIC50
6-prenylnaringenin	Antagonist	6.0	pIC50
anandamide	Antagonist	5.4	pIC50
ABT-639	Pore blocker	5.0	pIC50
Ni2+	Antagonist	3.8	pIC50

Binding affinities (BindingDB)

152 measured of 298 human assays (298 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
N-(3-chloro-5-fluorophenyl)-2-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	59.7 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-fluoro-5-methoxyphenyl)-2-[2-oxo-2-[[1-(trifluoromethyl)cyclobutyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	110 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
2-[2-(tert-butylamino)-2-oxoethyl]-N-(4-chloro-3-methoxyphenyl)-2-azaspiro[3.5]nonane-7-carboxamide	IC50	129 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-chloro-5-fluorophenyl)-2-[(4,4-difluoro-1-hydroxycyclohexyl)methyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	130 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-chloro-5-fluorophenyl)-2-[2-[(1-methylcyclopropyl)amino]-2-oxoethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	146 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-[3-(difluoromethoxy)-4-fluorophenyl]-2-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	149 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
2-[2-(tert-butylamino)-2-oxoethyl]-N-(3-chloro-5-methoxyphenyl)-2-azaspiro[3.5]nonane-7-carboxamide	IC50	159 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(4-chloro-3-methoxyphenyl)-2-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	162 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
US20250214932, Example 85	IC50	163 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-chloro-5-fluorophenyl)-2-(2-cyclohexyl-2-hydroxyethyl)-2-azaspiro[3.5]nonane-7-carboxamide	IC50	170 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-[3-(difluoromethyl)-5-fluorophenyl]-2-[2-(3,3-dimethylmorpholin-4-yl)-2-oxoethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	176 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(1-adamantyl)-2-[(4,4-difluoro-1-hydroxycyclohexyl)methyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	188 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-[3-(difluoromethyl)-5-fluorophenyl]-2-[2-[(1-methoxy-2-methylpropan-2-yl)amino]-2-oxoethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	191 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
2-[2-(tert-butylamino)-2-oxoethyl]-N-(3-fluoro-5-methylphenyl)-2-azaspiro[3.5]nonane-7-carboxamide	IC50	196 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-chlorophenyl)-2-[2-oxo-2-[[1-(trifluoromethyl)cyclobutyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	204 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
2-[2-(tert-butylamino)-2-oxoethyl]-N-(3-fluoro-5-methoxyphenyl)-2-azaspiro[3.5]nonane-7-carboxamide	IC50	218 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-chloro-4-fluorophenyl)-2-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	219 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-fluoro-5-methylphenyl)-2-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	221 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
US20250214932, Example 109	IC50	231 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-[3-(difluoromethoxy)phenyl]-2-[2-oxo-2-[(1,1,1-trifluoro-2-methylpropan-2-yl)amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	235 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-fluoro-5-methoxyphenyl)-2-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	238 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-chloro-5-fluorophenyl)-2-(3,3-dimethylbutyl)-2-azaspiro[3.5]nonane-7-carboxamide	IC50	252 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-[3-(difluoromethyl)-5-fluorophenyl]-2-[2-[[1-(trifluoromethyl)cyclobutanecarbonyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	261 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-chloro-5-fluorophenyl)-2-[2-[[1-(difluoromethyl)cyclopropyl]amino]-2-oxoethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	283 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-[3-(difluoromethyl)-5-fluorophenyl]-2-[2-[[1-(trifluoromethyl)cyclopropanecarbonyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	284 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
2-[2-(tert-butylamino)-2-oxoethyl]-N-(3-chlorophenyl)-2-azaspiro[3.5]nonane-7-carboxamide	IC50	294 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
2-[2-(tert-butylamino)-2-oxoethyl]-N-[3-(difluoromethoxy)phenyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	296 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-chloro-5-fluorophenyl)-2-[(1-cyanocyclopentyl)methyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	296 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-[4-fluoro-3-(trifluoromethoxy)phenyl]-2-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	297 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-[3-(difluoromethyl)-5-fluorophenyl]-2-[2-(1-methylcyclobutyl)ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	300 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
2-[2-(tert-butylamino)-2-oxoethyl]-N-(4-fluoro-3-methoxyphenyl)-2-azaspiro[3.5]nonane-7-carboxamide	IC50	300 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-chlorophenyl)-2-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	302 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
(1-methylcyclopropyl) N-[2-[7-[(3-chloro-5-fluorophenyl)carbamoyl]-2-azaspiro[3.5]nonan-2-yl]ethyl]carbamate	IC50	307 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
2-[2-oxo-2-[(1,1,1-trifluoro-2-methylpropan-2-yl)amino]ethyl]-N-[3-(trifluoromethoxy)phenyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	333 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-chloro-5-fluorophenyl)-2-[(1,4,4-trifluorocyclohexyl)methyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	333 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-[3-(difluoromethyl)-5-fluorophenyl]-2-[2-[methyl-(1-methylcyclobutyl)amino]-2-oxoethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	338 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
US20250214932, Example 86	IC50	344 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-chloro-5-fluorophenyl)-2-[(1-cyanocyclohexyl)methyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	352 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(1-bicyclo[2.2.2]octanyl)-2-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	357 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
US20250214932, Example 108	IC50	364 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-[3-(difluoromethoxy)-5-fluorophenyl]-2-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	366 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
2-[2-oxo-2-[(1,1,1-trifluoro-2-methylpropan-2-yl)amino]ethyl]-N-[3-(trifluoromethyl)phenyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	372 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
3-chloro-5-fluoro-N-[[2-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]ethyl]-2-azaspiro[3.5]nonan-7-yl]methyl]benzamide	IC50	373 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(4-fluoro-3-methylphenyl)-2-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	400 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(1-adamantyl)-2-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	404 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
2-(2-cyclopentyl-2,2-difluoroethyl)-N-[3-(difluoromethyl)-5-fluorophenyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	407 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
US20250214932, Example 113	IC50	415 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-(3-chloro-5-fluorophenyl)-2-[(1-cyano-4,4-difluorocyclohexyl)methyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	427 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
2-[2-(benzenesulfonyl)ethyl]-N-[3-(difluoromethyl)-5-fluorophenyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	428 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF
N-[3-(difluoromethyl)phenyl]-2-[2-oxo-2-[(1,1,1-trifluoro-2-methylpropan-2-yl)amino]ethyl]-2-azaspiro[3.5]nonane-7-carboxamide	IC50	430 nM	US-20250214932: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF

ChEMBL bioactivities

681 potent at pChembl≥5 of 739 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.00	IC50	1	nM	CHEMBL4206509
8.96	IC50	1.1	nM	CHEMBL4207291
8.96	IC50	1.1	nM	CHEMBL4214862
8.96	IC50	1.1	nM	CHEMBL4204077
8.92	IC50	1.2	nM	SUVECALTAMIDE
8.89	IC50	1.3	nM	CHEMBL4203101
8.85	IC50	1.4	nM	CHEMBL4211105
8.85	IC50	1.4	nM	CHEMBL4207031
8.82	IC50	1.5	nM	CHEMBL3891844
8.82	IC50	1.5	nM	CHEMBL4205005
8.72	IC50	1.9	nM	CHEMBL3890624
8.72	IC50	1.9	nM	CHEMBL4212039
8.66	IC50	2.2	nM	CHEMBL4208907
8.66	IC50	2.2	nM	CHEMBL4205399
8.66	IC50	2.2	nM	CHEMBL4204507
8.64	IC50	2.3	nM	CHEMBL4212176
8.64	IC50	2.3	nM	CHEMBL4207159
8.62	IC50	2.4	nM	CHEMBL3973392
8.62	IC50	2.4	nM	CHEMBL4215974
8.60	IC50	2.5	nM	CHEMBL4209946
8.59	IC50	2.6	nM	CHEMBL4204573
8.57	IC50	2.7	nM	CHEMBL3891844
8.55	IC50	2.8	nM	CHEMBL4218608
8.52	IC50	3	nM	CHEMBL3919024
8.51	IC50	3.1	nM	CHEMBL3919898
8.51	IC50	3.1	nM	CHEMBL4218161
8.49	IC50	3.2	nM	CHEMBL4216687
8.47	IC50	3.4	nM	CHEMBL4203748
8.47	IC50	3.4	nM	CHEMBL4203847
8.47	IC50	3.4	nM	CHEMBL4207979
8.46	IC50	3.5	nM	CHEMBL4209481
8.46	IC50	3.5	nM	CHEMBL4206219
8.40	IC50	4	nM	CHEMBL3924174
8.40	IC50	4	nM	CHEMBL3931239
8.40	IC50	4	nM	CHEMBL599833
8.38	IC50	4.2	nM	CHEMBL4208950
8.37	IC50	4.3	nM	CHEMBL4208626
8.35	IC50	4.5	nM	CHEMBL3965812
8.35	IC50	4.5	nM	CHEMBL4216756
8.35	IC50	4.5	nM	CHEMBL5917261
8.34	IC50	4.6	nM	CHEMBL4204873
8.30	IC50	5	nM	CHEMBL3913893
8.30	IC50	5	nM	CHEMBL3906199
8.30	IC50	5	nM	CHEMBL4205754
8.29	IC50	5.1	nM	CHEMBL4218617
8.25	IC50	5.6	nM	CHEMBL4205399
8.23	IC50	5.9	nM	CHEMBL3906126
8.22	IC50	6	nM	CHEMBL3936835
8.22	IC50	6	nM	CHEMBL3890916
8.21	IC50	6.2	nM	CHEMBL4209751

PubChem BioAssay actives

605 with measured affinity, of 1463 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[4-(3,3-difluorocyclobutyl)phenyl]-N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0010	uM
N-[1-[(4-chlorophenyl)methyl]pyrazol-3-yl]-2-[4-(dimethylamino)phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0011	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-[6-(3,3-difluoropyrrolidin-1-yl)-3-pyridinyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0011	uM
N-[1-[(5-cyano-2-pyridinyl)methyl]pyrazol-3-yl]-2-[3-ethyl-4-(2,2,2-trifluoroethoxy)phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0011	uM
2-(4-propan-2-ylphenyl)-N-[(1R)-1-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]ethyl]acetamide	1316446: Inhibition of T-type calcium channel Cav3.1 (unknown origin) expressed in HEK293 cells assessed as calcium influx by Fluo-4-AM dye-based FLIPR assay	ic50	0.0012	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-(1,3,3-trimethyl-2-oxoindol-5-yl)acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0013	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-(4-propan-2-ylphenyl)acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0014	uM
2-[4-(3,3-difluorocyclobutyl)oxyphenyl]-N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0014	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-[4-(dimethylamino)phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0015	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-(1H-indol-6-yl)acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0019	uM
2-[4-(dimethylamino)phenyl]-N-[1-[[4-(trifluoromethoxy)phenyl]methyl]pyrazol-3-yl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0022	uM
N-[1-[(5-cyano-2-pyridinyl)methyl]pyrazol-3-yl]-2-[3-methyl-4-(2,2,2-trifluoroethoxy)phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0022	uM
N-[1-[(5,5-difluorooxan-2-yl)methyl]pyrazol-3-yl]-2-(4-propan-2-ylphenyl)acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0022	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-(1H-indol-5-yl)acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0023	uM
N-[1-[(5-cyano-2-pyridinyl)methyl]pyrazol-3-yl]-2-[3-methyl-4-(trifluoromethoxy)phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0023	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-[4-(3-methyloxetan-3-yl)phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0024	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-[6-[(3S)-3-fluoropyrrolidin-1-yl]-3-pyridinyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0025	uM
N-[1-[(5-cyano-2-pyridinyl)methyl]pyrazol-3-yl]-2-[3-methyl-4-(3,3,3-trifluoropropoxy)phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0026	uM
2-(4-tert-butylphenyl)-N-[1-[(5-cyano-2-pyridinyl)methyl]pyrazol-3-yl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0028	uM
N-[1-[(4-cyano-3-fluorophenyl)methyl]pyrazol-3-yl]-2-[4-(dimethylamino)phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0031	uM
N-[1-[(3,5-difluoro-4-methoxyphenyl)methyl]pyrazol-3-yl]-2-[4-(dimethylamino)phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0032	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-(1-methylindazol-5-yl)acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0034	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0034	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-[4-(2,2-dimethyl-1,3-dioxolan-4-yl)phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0034	uM
N-[2-[(3,4-difluorophenyl)methyl]triazol-4-yl]-2-(1-methylindazol-5-yl)acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0035	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-[4-[(3-methyloxetan-3-yl)methoxy]phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0035	uM
(3R,5S)-3,5-dimethyl-N-pyridin-3-yl-1-[[5-(trifluoromethyl)furan-2-yl]methyl]-3,5-dihydro-2H-1,4-benzodiazepine-4-carboxamide	1325728: Channel blocking activity at recombinant human CaV 3.1 channel expressed in HEK293 cells assessed as inhibition of Ca2+ flux preincubated for 3 mins followed by CaCl2 addition by fluo-4 dye-based FLIPR assay	ic50	0.0040	uM
(3R,5S)-1-[(2-fluorophenyl)methyl]-3,5-dimethyl-N-pyridin-3-yl-3,5-dihydro-2H-1,4-benzodiazepine-4-carboxamide	1325728: Channel blocking activity at recombinant human CaV 3.1 channel expressed in HEK293 cells assessed as inhibition of Ca2+ flux preincubated for 3 mins followed by CaCl2 addition by fluo-4 dye-based FLIPR assay	ic50	0.0040	uM
2-[4-(dimethylamino)phenyl]-N-[1-[(4-fluorophenyl)methyl]pyrazol-3-yl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0042	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-[4-(3-fluorooxetan-3-yl)phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0043	uM
N-[4-[(3,4-difluorophenyl)methyl]-1,3-thiazol-2-yl]-2-(4-propan-2-ylphenyl)acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0045	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-[4-(oxetan-3-yloxy)phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0046	uM
(3R,5S)-N-benzyl-1-[(2,3-difluorophenyl)methyl]-3,5-dimethyl-3,5-dihydro-2H-1,4-benzodiazepine-4-carboxamide	1325728: Channel blocking activity at recombinant human CaV 3.1 channel expressed in HEK293 cells assessed as inhibition of Ca2+ flux preincubated for 3 mins followed by CaCl2 addition by fluo-4 dye-based FLIPR assay	ic50	0.0050	uM
(3R,5S)-N,1-dibenzyl-3,5-dimethyl-3,5-dihydro-2H-1,4-benzodiazepine-4-carboxamide	1325728: Channel blocking activity at recombinant human CaV 3.1 channel expressed in HEK293 cells assessed as inhibition of Ca2+ flux preincubated for 3 mins followed by CaCl2 addition by fluo-4 dye-based FLIPR assay	ic50	0.0050	uM
2-(4-tert-butylphenyl)-N-[1-[(3,4-difluorophenyl)methyl]-1,2,4-triazol-3-yl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0050	uM
N-(1-benzylpyrazol-3-yl)-2-(4-propan-2-ylphenyl)acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0051	uM
(3R,5S)-1-benzyl-8-fluoro-3,5-dimethyl-N-pyridin-3-yl-3,5-dihydro-2H-1,4-benzodiazepine-4-carboxamide	1325728: Channel blocking activity at recombinant human CaV 3.1 channel expressed in HEK293 cells assessed as inhibition of Ca2+ flux preincubated for 3 mins followed by CaCl2 addition by fluo-4 dye-based FLIPR assay	ic50	0.0060	uM
2-[4-(dimethylamino)phenyl]-N-[1-[(4-fluorophenyl)methyl]pyrazol-3-yl]propanamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0062	uM
N-[1-[(5-cyano-2-pyridinyl)methyl]pyrazol-3-yl]-2-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0064	uM
1-[(3,4-difluorophenyl)methyl]-N-[[6-(3,3-difluoropyrrolidin-1-yl)-3-pyridinyl]methyl]pyrazole-3-carboxamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0065	uM
N-[1-[[4-(difluoromethoxy)phenyl]methyl]pyrazol-3-yl]-2-[4-(dimethylamino)phenyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0068	uM
2-[4-(dimethylamino)phenyl]-N-[1-[(4-methylphenyl)methyl]pyrazol-3-yl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0070	uM
(3R,5S)-N,1-dibenzyl-8-fluoro-3,5-dimethyl-3,5-dihydro-2H-pyrido[2,3-e][1,4]diazepine-4-carboxamide	1325728: Channel blocking activity at recombinant human CaV 3.1 channel expressed in HEK293 cells assessed as inhibition of Ca2+ flux preincubated for 3 mins followed by CaCl2 addition by fluo-4 dye-based FLIPR assay	ic50	0.0070	uM
(3R,5S)-N-benzyl-3,5-dimethyl-1-[[5-(trifluoromethyl)furan-2-yl]methyl]-3,5-dihydro-2H-1,4-benzodiazepine-4-carboxamide	1325728: Channel blocking activity at recombinant human CaV 3.1 channel expressed in HEK293 cells assessed as inhibition of Ca2+ flux preincubated for 3 mins followed by CaCl2 addition by fluo-4 dye-based FLIPR assay	ic50	0.0070	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-(1-methylpyrrolo[2,3-b]pyridin-5-yl)acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0071	uM
(3R,5S)-1-[(3-fluorophenyl)methyl]-3,5-dimethyl-N-pyridin-3-yl-3,5-dihydro-2H-1,4-benzodiazepine-4-carboxamide	1325728: Channel blocking activity at recombinant human CaV 3.1 channel expressed in HEK293 cells assessed as inhibition of Ca2+ flux preincubated for 3 mins followed by CaCl2 addition by fluo-4 dye-based FLIPR assay	ic50	0.0080	uM
(3R,5S)-1-benzyl-N-[(4-methoxyphenyl)methyl]-3,5-dimethyl-3,5-dihydro-2H-1,4-benzodiazepine-4-carboxamide	1325728: Channel blocking activity at recombinant human CaV 3.1 channel expressed in HEK293 cells assessed as inhibition of Ca2+ flux preincubated for 3 mins followed by CaCl2 addition by fluo-4 dye-based FLIPR assay	ic50	0.0080	uM
2-[4-(dimethylamino)phenyl]-N-[1-[(3-methylphenyl)methyl]pyrazol-3-yl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0081	uM
methyl 5-[3-(1H-benzimidazol-2-yl)propyl-methylamino]-2-(4-bromophenyl)-2-propan-2-ylpentanoate	1069083: Inhibition of T-type calcium channel subunit alpha-1G (unknown origin) expressed in HEK293 cells assessed as inactivation of channel current at holding potential of 30 to 100mV by whole-cell patch clamp method	ic50	0.0082	uM
N-[1-[(3,4-difluorophenyl)methyl]pyrazol-3-yl]-2-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]acetamide	1367821: Inhibition of recombinant Cav3.1 (unknown origin) expressed in HEK293 cells assessed as decrease in calcium flux preincubated for 3 mins followed by CaCl2 addition by Fluo-4-AM dye-based FLIPR assay	ic50	0.0100	uM

CTD chemical–gene interactions

53 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, affects cotreatment, increases expression	5
bisphenol A	affects cotreatment, increases methylation, decreases expression	3
Doxorubicin	affects expression, decreases expression	3
trichostatin A	increases expression	2
Barium	increases transport, decreases reaction	2
Daunorubicin	decreases expression	2
Estradiol	increases expression, decreases expression, affects cotreatment	2
Mitoxantrone	decreases expression	2
aristolochic acid I	increases expression	1
methylmercuric chloride	increases expression	1
propionaldehyde	increases expression	1
sodium arsenite	increases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
pentanal	increases expression	1
pentabromodiphenyl ether	decreases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	decreases methylation	1
Fulvestrant	affects cotreatment, increases methylation	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Cerium	increases transport, decreases reaction	1
Chelating Agents	affects binding, increases expression	1
Cisplatin	decreases expression	1
Copper	affects binding, increases expression	1

ChEMBL screening assays

105 unique, capped per target: 91 binding, 11 functional, 2 admet, 1 toxicity

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4331799	Binding	Inhibition of T-type calcium channel (unknown origin)	The discovery and optimization of benzimidazoles as selective NaV1.8 blockers for the treatment of pain. — Bioorg Med Chem
CHEMBL1060568	Functional	Antagonist activity against T-type calcium channel alpha1G	Quinazolindione derivatives as potent 5-HT3A receptor antagonists. — Bioorg Med Chem
CHEMBL4180612	ADMET	Inhibition of recombinant human Cav3.1 expressed in HEK293 cells assessed as reduction in CaCl2-induced intracellular calcium flux incubated for 20 mins measured at 10 secs interval for 2 to 6 mins by Fluo-4AM dye based FLIPR assay	Discovery and evaluation of Cav3.2-selective T-type calcium channel blockers. — Bioorg Med Chem Lett

Cellosaurus cell lines

7 cell lines: 3 cancer cell line, 3 induced pluripotent stem cell, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7L9	Ubigene A-549 CACNA1G KO	Cancer cell line	Male
CVCL_D8I3	Ubigene HCT 116 CACNA1G KO	Cancer cell line	Male
CVCL_D9YZ	Ubigene HeLa CACNA1G KO	Cancer cell line	Female
CVCL_E4TX	KOLF2.1J CACNA1G 58.1kbdel DEL/DEL	Induced pluripotent stem cell	Male
CVCL_E7JS	KOLF2.1J CACNA1G R1274S SNV/SNV	Induced pluripotent stem cell	Male
CVCL_E7JT	KOLF2.1J CACNA1G R1274S SNV/WT	Induced pluripotent stem cell	Male
CVCL_HC62	HEK293 Cav3.1	Transformed cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study